What it's for (Indications)
- Irbesartan is an angiotensin II receptor blocker (ARB) primarily indicated for the management of essential hypertension.
- Its therapeutic action in lowering elevated blood pressure helps to reduce the risk of associated cardiovascular morbidity and mortality, including stroke, myocardial infarction, and heart failure.
- It is used either as monotherapy or in combination with other antihypertensive agents to achieve target blood pressure goals, based on individualized patient assessment and current treatment guidelines.
- Furthermore, irbesartan is specifically indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension.
- In this population, it is utilized to delay the progression of renal disease, as evidenced by a reduction in the rate of decline in glomerular filtration rate and a reduction in proteinuria (macroalbuminuria or microalbuminuria).
- This action is crucial in mitigating the risk of end-stage renal disease and the subsequent need for renal replacement therapies such as dialysis or kidney transplantation.
- Regular monitoring of renal function and electrolyte levels is essential during treatment to ensure optimal patient outcomes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For essential hypertension, the recommended initial dose is 150 mg once daily, which can be increased to a maximum of 300 mg once daily for blood pressure control. For nephropathy in type 2 diabetic patients, the recommended dose is 300 mg once daily. In patients with intravascular volume or salt depletion (e.g., those on vigorous diuretic therapy or hemodialysis), an initial dose of 75 mg once daily is recommended. Irbesartan can be administered with or without food and may be used with other antihypertensive agents. |
Safety & Warnings
Common Side Effects
- Commonly reported side effects include dizziness (including orthostatic dizziness), headache, and back pain.
- Other important adverse reactions may include hypotension (especially in volume or salt-depleted patients), hyperkalemia, impaired renal function, and orthostatic hypotension.
Serious Warnings
- Black Box Warning: WARNING: FETAL TOXICITY. When pregnancy is detected, discontinue irbesartan as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
- Patients receiving vigorous diuretic therapy, those with kidney disease (including transplantation), heart disease, or primary aldosteronism should exercise caution.
- Diabetic patients, particularly those with type 2 diabetes and nephropathy, require careful monitoring.
- Volume or salt-depleted patients are at increased risk of hypotension.
- This medication may cause drowsiness, thereby decreasing the ability to drive or operate machinery.
- Alcohol consumption should be avoided.
How it Works (Mechanism of Action)
Irbesartan is an Angiotensin II Receptor Blocker (ARB) that selectively binds to the AT1 angiotensin II receptor. It blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II, which is a primary vasoactive hormone of the renin-angiotensin system and contributes to the pathophysiology of hypertension.